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tool and extrapolated into N/V levels as: grade A (none to mild
nausea; no emesis recorded), grade B (moderate nausea; no emesis
recorded), or grade C (moderate nausea for more than half the
time, or any severe nausea or any emesis). Lorazepam and dolas-
etron were used prophylacticly from beginning of chemotherapy
through day1. Oral prochlorperazine was given prn. Results: 23
of 29 of patients experienced Grade A N/V during conditioning-
reinfusion phase. All patients received anti-emetic irrespective of
N/V grade. During Day 1 to Day 10, 13 of 29 patients expe-
rienced no higher than Grade A N/V, with 8 of those 13 requiring
anti-emetics. During Day 11 to Day 14, 19 of 29 had Grade A
N/V with 3 of those 19 requiring anti-emetics. A higher percent-
age (50%) of melphalan patients experienced Grade C N/V than
with BEAC (16%) or CBV (20%) in the third phase. 1 melphalan
patient and 1 BEAC patient required dronabinol to control per-
sistent N/V. Conclusions: Melphalan appears to cause more se-
vere and more delayed/extended N/V than BEAC or CBV. Pa-
tients receiving melphalan appeared signiﬁcantly less likely to
progress through PBSCT without receiving any anti-emetics.
While more patients are required to strengthen statistical signiﬁ-
cance, we believe these ﬁndings are predictive of N/V associated
with these three conditioning regimens. Further study should as-
certain improved approaches to N/V assessment and management.
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Methods: A retrospective chart review was conducted on 49
patients receiving autologous stem cell transplants in the outpa-
tient setting within a three year time frame. The patients were
transplanted for multiple myeloma (MM), Hodgkin’s lymphoma
(HD), or Non-Hodgkin’s lymphoma (NHL). The analysis consid-
ered: age at transplant, past medical history, disease status at
transplant, and outcomes of pretesting, to determine what charac-
teristics might predispose for hospital admission. Results: Thir-
teen patients were admitted from the outpatient setting, 8 for
sepsis/neutropenic fever, 3 for dehydration or vomiting, 1 for
mental status changes, and one for cardiac failure. Of the 13
(thirteen) patients requiring hospital admission, 12 had a disease
status at time of transplant of partial remission (PR), 1 (with 3 prior
relapses) was in complete remission (CR) prior to PBSCT. One
patient was admitted after white blood cell engraftment and one
admitted during chemotherapy administration. Of the patients not
requiring hospital admission from the outpatient setting, 14 were
PR, 16 were CR, 5 were relapsed with chemosensitive disease, and
1 was Rel1 (ﬁrst relapse after a CR). In the chart review, no
statistical correlations were found between the admitted and non-
admitted groups for: age, past medical history, and pretest indica-
tors. Conclusions: Patients with MM had a higher rate of hospital
admission from the outpatient setting versus those with either HD
or NHL. The incidence of hospitalization seems to be especially
prevalent in patients whose disease processes were not in complete
remission. This analysis suggests a correlation of disease and pre-
transplant status as a predictor of hospital admission; however,
further study is indicated.
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Background: Response rates with existing monotherapy for IA
remain suboptimal, and mortality remains unacceptably high.
Anidulafungin is a novel echinocandin (EC) in late stage develop-
ment with potent in vitro activity that is additive or synergistic with
amphotericin B (AmB) against Aspergillus spp. ANID’s distinct PK
characteristics and favorable safety proﬁle support development as
a ﬁrst-line therapeutic agent. AmB has efﬁcacy for IA but has
unacceptable toxicity. Combination of ANID and LAmB may offer
improved outcome with no excessive toxicity. The safety of com-
bination ANID plus LAmB was evaluated. Methods: Pts  18 yrs
with proven or probable IA (per EORTC, MSG criteria) and life
expectancy  72 hrs were enrolled into an open-label, non-com-
parative study. Exclusion criteria included receipt of more than 5
days of antifungal therapy (unless treatment failure) and AST/
ALT 5 X ULN. ANID was given as 200 mg IV loading dose day
1 with 100 mg daily maintenance (200/100mg); LAmB was given
daily up to 5 mg/kg/day. Treatment continued until resolution of
signs/symptoms up to 90 days. Clinical assessments were done on
therapy, end of therapy (EOT) and at 4 weeks post EOT (FU).
Safety labs and ECGs were performed. Results: Data on 17 of 30
enrolled patients are presented. Mean age was 55 (range 21-79).
The majority of pts had pulmonary IA (12); other sites included
CNS (2), cutaneous, hepatic and bone (1 each). Risk factors for IA
were steroid use (3); AML (3); ALL (1); other malignancies (2);
aplastic anemia (1) and other malignancies (2); allogeneic BMT (3);
heart (1) or liver transplant (1). 12 of 17 patients had at least 1
drug-related adverse event (DRAE). Of these pts, 7 and 3 had an
AE expected with LAmB and with LAmB and/or ANID, respec-
tively. DRAEs reported in  2 pts were hypokalemia, increased
transaminases, increased ALP, hypomagnesemia and ﬂushing. 14
pts had a total of 22 serious AEs; only 2 were drug related (renal
failure, an expected event for LAmB; abnormal LFTs). There were
9 deaths during the 90 day study period; none considered related to
study drug. No trends attributable to ANID/LAmB were seen for
post-baseline hematology or chemistry results. Conclusions: The
patterns of AEs and laboratory abnormalities were not unexpected
for this ill population. No untoward safety ﬁndings were found.
Based upon available data, ANID and LAmB can be safely co-
administered.
Table. Patients Experiencing N/V by Grade by PBSCT Phase
Patients Grouped by Grade N/V per PBSCT Phase
Conditioning
Regimen
Level of
N/V
Conditioning-
Reinfusion
Day 7 to
Day 0 (% of
Patients)
Day 1
through Day
10 (% of
Patients)
Day 11
through Day
14 (% of
Patients)
Melphalan
(n  12)
Grade C 3 (25%) 6 (50%) 6 (50%)
Grade B 0 (0%) 2 (16%) 0 (0%)
Grade A 9 (75%) 4 (33%) 6 (50%)
BEAC
(n  12)
Grade C 1 (8%) 4 (33%) 2 (16%)
Grade B 0 (0%) 2 (16%) 0 (0%)
Grade A 11 (92%) 6 (50%) 10 (84%)
CBV
(n  5)
Grade C 2 (40%) 2 (40%) 1 (20%)
Grade B 0 (0%) 0 (0%) 1 (20%)
Grade A 3 (60%) 3 (60%) 3 (60%)
Table. Frequency of Hospitalization Among Disorders
Disease Patients Admitted Patients Not Admitted
MM (n  20) 9 (45.0%) 11 (55.0%)
HD (n  9) 2 (22.2%) 7 (77.8%)
NHL (n  20) 2 (10.0%) 18 (90.0%)
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